Company / PP&E (Net)
IOVANCE BIOTHERAPEUTICS, INC. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$131.1M
FY2025
5-year range
$100.9M / $131.1M
FY2021-FY2025
Trend
+20.2%
vs FY2024
Sector context
#38 of 193
Health Care
What the data says
IOVANCE BIOTHERAPEUTICS, INC.'s pp&e (net) of $131M is higher than 80% of companies in the Health Care sector (FY2025). Improved from $114M to $131M over the past 2 years.
Based on SEC 10-K filings.
$131M in FY2025 with a 5-year CAGR of +17.3%. Top quartile in the Health Care sector.
Improved from $114M to $131M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +7.6%
- 5-Year CAGR
- +17.3%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 193This company $131.1M Sector average $777.6M
▼
-83.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.3%, indicating consistent growth.
- In FY2025, pp&e (net) increased 20.2% year-over-year.
- Ranks #38 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $131.1M | +20.2% |
| FY2024 | $109.1M | -4.3% |
| FY2023 | $114.0M | +8.4% |
| FY2022 | $105.2M | +4.3% |
| FY2021 | $100.9M | +70.6% |
| FY2020 | $59.2M | +593.1% |
| FY2019 | $8.5M | +218.2% |
| FY2018 | $2.7M | +9.5% |
| FY2017 | $2.5M | +3.2% |
| FY2016 | $2.4M | +41.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026